Generate Biomedicines Expands Board of Directors With Jane Mendillo, Former CEO of The Harvard Management Company

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 7, 2022--

Generate Biomedicines today announced that Jane Mendillo has been appointed to its board of directors. Ms. Mendillo brings impressive investment and financing expertise to the machine-learning-powered biotech.

“As Generate approaches the early stages of clinical development in 2023, we are strengthening our board with experienced leaders who can help us build a transformative company,” said Noubar Afeyan, co-founder and Chairman of Generate and CEO of Flagship Pioneering. “Jane’s breadth of experience leading and running organizations and financial markets expertise is a welcome addition to the board as we look to rapidly scale Generate. I am excited to welcome her to the board.”

“I’m thrilled to be joining Generate’s board as its innovative team is pioneering generative biology to develop better medicines for patients faster,” noted Mendillo. “I look forward to working with the board and management of this dynamic company.”

With over 30 years of investment management experience, Ms. Mendillo serves on the board of Lazard Ltd., one of the world’s preeminent financial advisory and asset management firms with operations in 40 cities across 25 countries. She is also a senior investment advisor for several private family offices, including the Old Mountain Private Trust Company. Until earlier this year, she was on the board of General Motors. She supports non-profit organizations as a trustee at Berklee College of Music and a board member at the think tank Council on Foreign Relations.

Ms. Mendillo spent over 20 years working at the Yale Investment Office, the Harvard Management Company, and then Wellesley College in various roles managing their endowments and investments. In 2008, she returned to Harvard as Chief Executive Officer of the management company, where she was responsible for the university’s approximately $37 billion global endowment and related assets for six years. Under her leadership, Harvard became the first university endowment to join the PRI, a United Nations-supported network of investors committed to promoting sustainable investments by incorporating environmental, social and governance factors into investment decision-making.

Ms. Mendillo has received many honors, including the 100 Women in Hedge Funds 2007 Leadership Award for her “talent, ethics and passion, which help define the industry’s standard of excellence.” She was named one of Forbes 100 Most Powerful Women in 2008 and 2009.

Ms. Mendillo received her bachelor of arts degree from Yale College and her master’s of business administration from the Yale School of Management.

About Generate Biomedicines

Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company’s platform represents a potentially fundamental shift in what’s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020. Learn more about Generate Biomedicines by visiting https://generatebiomedicines.com/ or following the company on Twitter and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20221207005280/en/

CONTACT: Media

Megan McLaughlin

pr@generatebiomedicines.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH SCIENCE PHARMACEUTICAL RESEARCH

SOURCE: Generate Biomedicines

Copyright Business Wire 2022.